Therefore, our data provide the preclinical evidence that adjuvant HER2-targeted therapy could enhance the radiotherapy efficacy in patients with recurrent HER2-negative breast cancer with elevated serum HER2. The gene discussed is ERBB2; the disease is breast carcinoma.